NCT02034773View on ClinicalTrials.gov

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Healthy Volunteers
Interventions
DRUG

CC-220

CC-220 0.3mg will be administered once daily for 14 days

DRUG

CC-220

CC-220 1mg will be administered once daily for 28 days + 1 dose of tetanus toxoid vaccination and 1 dose of pneumococcal vaccination

DRUG

CC-220

CC-220 0.3mg will be administered once daily for 28 days

DRUG

CC-220

CC-220 1mg will be administered once daily for 7 days on 2 separate occasions, with a 7-day washout in between, for a total of 14 days of dosing

DRUG

Placebo

Placebo will be administered once daily for up to 28 days

DRUG

CC-220

CC-220 0.3mg will be administered every 3 days for 14 days (5 total doses)

DRUG

CC-220

CC-220 1mg (once every 7 days for 28 days)

DRUG

CC-220

CC-220 1mg will be administered as a single dose in each of 2 study periods; once as a formulated capsule and once as two reference capsules

Trial Locations (1)

53704

Covance Clinical Research Unit, Madison

Sponsors
All Listed Sponsors
lead

Celgene Corporation

INDUSTRY

NCT02034773 - 3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule | Biotech Hunter | Biotech Hunter